Skip to main content
Equibles
DMAC logo

DMAC · DiaMedica Therapeutics Inc.

Track DMAC — free

Use DMAC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.75 +0.19 (+2.90%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$364.00M
Shares
53.93M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.75 Open$6.56 Day$6.49–6.89 52W close$5.33–9.39 Avg vol 30d144K Short int5.4M · 9.9% float · 37.9d Short vol62% Last earningsAug 11, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Nov 13, 2026 Est · unconfirmed · in 10 wks
Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$37.54M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-1,352.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$43.50M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.1%
Year over year · more shares
Price change (1Y)
+25.7%
Trailing year
Short interest
9.9%
Latest settlement · 37.9 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Bearish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −2%
below
RSI (14) 53
neutral
MACD trend Positive
52-week position 35%
mid-range
Momentum
relative strength
Very Weak
1-month return 0%
trailing
6-month return −6%
trailing
YTD return −15%
this year
Relative strength −21%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.93% of float · ▲ +2.9% MoM · 37.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
88 holders — mid 3-yr range
Squeeze score 75
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 58%
annualized · 1-yr
Max drawdown −43%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−2% Neutral
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
35% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +11 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.93% of float · ▲ +2.9% MoM · 37.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
88 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5 Now $7 · 35% Range high $9
vs 200-day avg -6% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DMAC
DiaMedica Therapeutics Inc.
this stock
$364.00M -15.2% — — 9.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.42B +20.5% +46.2% 31.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.22B +7.2% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $64.25B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $60.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
88
% held
23.1%
Net QoQ
+700.5K sh
Top holder
COOPERMAN LEON G
Held Float
View
Held by Funds
Fund positions
80
View
Short & Settlement
Short Interest Rising
Shares short
5.4M
Days to cover
37.9d
Change
+152.2K sh
View
Short Volume
Short vol %
62%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
11.4K
Value
$78.3K
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
29.0%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-32.8M
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
9
View
Proposed Sales
Value
$109.5K
Shares
39.7K
Filed
Jul 2, 2024
View
Exempt Offerings
Offering
$30.1M
Filed
Jul 25, 2025
View
Earnings & Events
Earnings Calls
Last call
Aug 11, 2026
View

Performance

5D 20D 120D MTD YTD
DMAC +5.6% +0.0% -6.0% +6.3% -15.2%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY +5.5% +0.4% -21.1% +5.9% -28.1%
Key facts CIK 1401040 CUSIP 25253X207 13F (30d) 58 filings 58 filers Visit website